More than 25 Years of Archived Biomedical and Pharmacological Records Acessible in Electronic Format

Thomson CorporationThomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, today announced that it has added EMBASE® Classic to the Dialog® (File 772) and DataStar® (EM73, EMXX) platforms, providing access to more than 25 years of archived life sciences data available for the first time in electronic format.

EMBASE Classic, produced by Elsevier, includes the bibliographic records originally published in the 43 Excerpta Medica abstract print journals from 1947 through 1973. The fully digitized database is drawn from approximately 3,400 international journal titles, with a focus on European and North American published literature including non-English language articles. EMBASE Classic contains more than 1.8 million records from the biomedical and pharmacological literature. The historical data in EMBASE Classic, combined with up-to-date records in the EMBASE database (File 73/EMZZ), gives researchers approximately 60 years of information regarding medical and drug-related subjects.

"With EMBASE Classic, researchers can now review advancements made during an extremely fertile period for the sciences, particularly in the areas of molecular biology, marine sciences, vaccines and other drug therapies," said Geoffrey Dick, Director of Publisher Management, Thomson Scientific. "The archived literature should prove invaluable in reviews of toxicology, adverse events and prior art for patent prosecution."

EMBASE Classic enhances research in:

  • Drug development
  • Pipeline intelligence
  • Designing and mounting clinical investigations
  • New uses for old drugs
  • Approved uses for drugs
  • Adverse events and reactions monitoring on old drugs or endogenous compounds
  • Preparation of new drug applications
  • Product safety and compliance monitoring

EMBASE Classic significantly expands the collection of biomedical and pharmacological literature sought by research professionals. The new database complements current Dialog and DataStar life sciences offerings, including EMBASE® (1974+ in File 73/EMZZ), as well as the recently added BIOSIS Previews® (File 5/BIOL), Zoological Record Online® and MEDLINE (1951+ in File 155/MEZZ) archive data.

For more information about the EMBASE Classic database on Dialog and DataStar, visit www.dialog.com/embaseclassic.

About The Thomson Corporation
The Thomson Corporation is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).

Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development-from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at http://scientific.thomson.com.

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Ancient viral DNA in human genome guards against i…

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new res...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...